Accepted for/Published in: JMIR Research Protocols
Date Submitted: Dec 20, 2023
Date Accepted: Feb 1, 2024
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Effectiveness of Chinese herbal medicine as a complementary treatment for neutropenia prevention and immunity modulation during chemotherapy in patients with breast cancer: study protocol for a real-world pragmatic clinical trial
ABSTRACT
Background:
In recent years, advancements in cancer treatment have enabled cancer cell inhibition, leading to improved patient outcomes. However, the side effects of chemotherapy, especially leukopenia, impact patients’ ability to tolerate their treatments and affect their quality of life (QoL). Traditional Chinese medicine (TCM) is thought to provide complementary cancer treatment to improve the QoL and prolong survival time among patients with cancer. This study aims to evaluate the effectiveness of Chinese herbal medicine (CHM) as a complementary treatment for neutropenia prevention and immunity modulation during chemotherapy in patients with breast cancer.
Objective:
This study aims to evaluate the efficacy of CHM as an add-on therapy for neutropenia and immunomodulation in patients with breast cancer.
Methods:
We will conduct a real-world pragmatic clinical trial to evaluate the effectiveness of CHM as a supplementary therapy to prevent neutropenia in patients with breast cancer undergoing chemotherapy. Patients will be classified into CHM or non-CHM groups based on whether they received CHM during chemotherapy. Employing generalized estimating equations or repeated-measures ANOVA, we will assess differences in white blood cell counts, absolute neutrophil counts, immune cells, and PD-1 expression levels between the two groups.
Results:
The enrollment process began in September 2021 and stopped in December 2023. A total of 60 patients will be recruited. Data cleaning and analysis are expected to finish in the middle of 2024.
Conclusions:
TCM is the most commonly used complementary medicine, which has been reported to significantly alleviate chemotherapy-related side effects. This study's findings may contribute to developing effective interventions targeting chemotherapy-related neutropenia among patients with breast cancer in clinical practice. Clinical Trial: This study was registered on the International Traditional Medicine Clinical Trial Registry (ITMCTR) website (ID: ITMCTR2023000054).
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.